GoodRx (GDRX) announced a new partnership with Boehringer Ingelheim to provide discounts for a biosimilar to rheumatoid arthritis drug Humira Thursday, adding to an increasingly competitive market.

GoodRx is joining forces with drugmaker Boehringer Ingelheim to make its Humira biosimilar adalimumab available at an affordable price. The pharmaceutical company will offer citrate-free ...

(Reuters) - A close copy version of Abbvie's blockbuster arthritis drug Humira will be available at a 92% discount to its list price on the GoodRx website, the digital healthcare platform and German ...

Drugmaker Boehringer Ingelheim and prescription savings platform GoodRx have teamed up to provide Boehringer’s Humira biosimilar for an exclusive cash price on GoodRx, the companies announced Thursday ...

In the year since the Humira biosimilar floodgates opened, AbbVie’s star immunology player has proven tough to drown out. In a new effort to crack the popular immunology drug’s 82% grasp on the market ...

GoodRx (NASDAQ:GDRX) and Boehringer Ingelheim on Thursday announced an initiative to launch the German drugmaker’s biosimilar against AbbVie’s (NYSE:ABBV) Humira (adalimumab) at an exclusively low ...

RIDGEFIELD, Conn. and SANTA MONICA, Calif., July 18, 2024 /PRNewswire/ -- Boehringer Ingelheim and GoodRx, the leading prescription savings platform in the U.S., announced today a patient ...

Boehringer Ingelheim and GoodRx are launching a patient affordability initiative to provide citrate-free Adalimumab-adbm, Boehringer’s biosimilar to Humira (adalimumab), at a low cash price available ...